Pelosi's plan would have Medicare pay no more than 1.2 times the average prices paid in the U.K., Germany, Australia, Canada, Japan and France for many drugs. (Photo: Shutterstock)
(Bloomberg Opinion) –Every time Congress tries to take on drug prices, it runs into the pharmaceutical lobby's timeworn objection: Lowering prices even a penny would end all drug innovation, allowing cures to slip through our fingers and dimming the flickering hopes of desperate patients.
This doomsday argument has worked for decades, but House Speaker Nancy Pelosi's drug-price negotiation legislation is putting it to the test. A Congressional Budget Office analysis finds that the lower prices envisioned by her bill would barely slow new drug discovery at all.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
